Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy November 8, 2023November 8, 2023
Alterity Therapeutics Successfully Completes Securities Purchase Plan (SPP) February 2, 2024February 2, 2024